The Challenge:
Molecular glue (MG), as an innovative modality, holds significant potential in drug discovery. MGs can be characterized by distinct binding and kinetic pathways that result in ternary complex formation. Currently, the prospective and rationale discovery of MG is still in its infancy, and there is a lack of comprehensive theoretical models to answer the key questions: What do the best MG opportunities look like? When is the risk too high to initiate a MG project?

The Goal:
To develop a computational model based on MG ternary binding and kinetics, to guide decision making on project initiation, and key optimisation strategies

The Solution:
We are seeking proposals to achieve the goal above, by considering following points:

• Two major kinetic paths for ternary complex formation
• For each path consider following factors to predict key outcomes including 1) level of POI (protein of interest) degradation achievable, to guide MG project go/no-go; and 2) understanding dominant factor(s) driving the level of POI degradation, to guide optimisation strategy
• Effector protein (EP), POI expression ratio
• EP-POI binding kinetics and affinity
• EP, POI turnover rate
• MG binary binding kinetics, affinity, and ternary binding kinetics, affinity
• Apply literature examples to validate the model (e.g.  GluN2B-ifenprodil-GluN1, FKBP12-rapamycin-FRAP, CRBN-IMID-IKZF systems)

The Challenge:​
While the association between nucleotide repeat expansion toxicity and muscle and CNS disorders is well-established, current strategies face challenges in effectively mitigating the toxicity​.

The Goal:​
We aim to collaboratively uncover and advance groundbreaking approaches for mitigating nucleotide repeat expansion toxicity​.

The Solution:​
We are seeking innovative strategies or novel concepts for mitigating nucleotide repeat expansion toxicity, with the potential to be applied in the treatment of muscle or CNS diseases​.

The Challenge:​
Engagement of patient communities is an important part of the design, recruitment and conduct of clinical trials. Fostering relationships between research sites and patient communities creates new opportunities for patients to get more information about and access to clinical trials.

​The Goal:​
Inclusion of patient communities in the design, recruitment and conduct of clinical trials. We are seeking innovative approaches of patient communities' engagement in clinical trials with CVRM diseases.​​

The Solution:​
The innovative solutions can cover networks, databases, AI, mobile devices, digital channels and collaborations with all kinds of patient communities. The solutions may include but are not limited to social media. Practical applicability in clinical CVRM trials is key to consider the solution applicable.

The Challenge:
The potential for treating devastating diseases that affect CNS, kidney, or muscle tissues has been constrained by the absence of targeted tissue-specific delivery, expression or regulation methods

The Goal:
Our goal is to uncover innovative methods for tissue-specific delivery as well as selective tissue-specific expression or regulation that can substantially enhance the therapeutic efficacy and safety profile of our novel molecules.

The Solution:
We are seeking innovative approaches for the targeted delivery of drugs to enhance the selectivity of genomic medicines in CNS, bone, kidney or cardiac muscles.